The genetic mutation for Marfan syndrome is on the Fibrillin-1 gene, but certain symptoms are not explained by this mutation. According to Grover et al., (2012) research, evidence shows that the skeletal variations are linked to faulty transforming growth factors (TGF-ß) signaling properties. The experiment on TGF-ß will be conducted through a mouse model. A mouse—with Marfan syndrome—will receive beta-blocker therapy or the TGF- ß regulation treatment. The TGF- ß signaling will be regulated in this experiment. The mice will be compared to each other along with a control group to determine the success of the study. The bone growth, density, mass, structure etc. will be recorded. TGF- ß could be affected by the mutation in Fibrillin-1 gene or it could be a separate mutation found in Marfan syndrome patients; these hypotheses will be taken into consideration after reviewing the
The genetic mutation for Marfan syndrome is on the Fibrillin-1 gene, but certain symptoms are not explained by this mutation. According to Grover et al., (2012) research, evidence shows that the skeletal variations are linked to faulty transforming growth factors (TGF-ß) signaling properties. The experiment on TGF-ß will be conducted through a mouse model. A mouse—with Marfan syndrome—will receive beta-blocker therapy or the TGF- ß regulation treatment. The TGF- ß signaling will be regulated in this experiment. The mice will be compared to each other along with a control group to determine the success of the study. The bone growth, density, mass, structure etc. will be recorded. TGF- ß could be affected by the mutation in Fibrillin-1 gene or it could be a separate mutation found in Marfan syndrome patients; these hypotheses will be taken into consideration after reviewing the